Pharmaceutical and biological industry 30 stocks on the list of 100 yuan shares, accounting for 26.79 percent

Pharmaceutical Network Pharmaceutical Stock Market: As one of the signals to determine the heat of the market, 100 yuan stocks have been the concern of investors.
the close of trading on September 9, the average A-share price was 11.29 yuan, of which 112 were trading above 100 yuan in two markets, according to the Securities Times.
In the new 100 yuan shares, to Shenwan first-class industry classification, the more concentrated industries are pharmaceutical biology, electronics, computers and so on, of which, the pharmaceutical and biological industry has 30 stocks on the list, accounting for 26.79 percent of the total number of 100 yuan shares.
from the two cities high-priced stocks, the top 10 list of Chinese medicine biology in the field of four stocks.
, Kanghua Bio's new closing price was 463.51 yuan, up -8.03 percent, with a 4.2 percent change rate.
public information shows that Kanghua Bio was founded in 2004, the company is equipped with animal testing center, high-tech level of bacteria and virus vaccine GMP production workshop, the main business includes the prevention of biological products production, sales, research, development and technical services, the existing products include "ACYW135 group meningococcal polysaccharide vaccine" (commodity name: Medu) and "frozen human rabies vaccine (human diosis cells)."
, the human rabies vaccine contributes more than 90% of sales.
according to the prospectine, "Frozen rabies vaccine (human secondary cells) in 2017, 2018 and 2019 sales revenue of 241 million yuan, 551 million yuan, 538 million yuan, accounting for 92.21 percent, 98.53 percent, 96.97 percent, respectively."
recent years, the total number of annual issuances of rabies vaccines for domestic use has remained at 60-80 million, with a large overall batch issuance base.
but the market penetration rate is not high.
2019, about 2.38 million vaccines were approved, accounting for only 4% of the total rabies vaccine market.
June 16th, Kanghua Bio was listed on the Shenzhen Stock Exchange, taking advantage of the spring breeze of the concept of bio-vaccines with a combination of vaccines for the Vaccine Trusted and Rabies vaccine.
August 4, Kanghua Bio reached a peak of 996 yuan, a rise of more than 10 times.
but soon there was a correction in volatility.
industry believes that the small Kanghua creature is facing pressure from challengers.
,000 yuan, up -2.71 percent, with a 1.07 percent change rate.
two years, Changchun Gaosing's share price has more than quadrupled.
industry analysis that Changchun high-rise can ride the east wind of the pharmaceutical sector all the way up, its logic is that Jinsai growth hormone performance and growth rate beautiful.
high technical barriers to growth hormone, clear demand, can be said to be a rising star in pharmaceutical consumption.
the current domestic market pattern is basically monopolized by Jinsai Pharmaceuticals.
2019, the size of the domestic growth hormone market close to 6 billion yuan, a growth rate of 40.54 percent.
and Kinsey Pharmaceuticals market share reached 74%, followed by Anke Bio, Shanghai United Searle, market share of 15%, 8%, respectively.
the rapid growth of Jinsai Pharmaceuticals, its profit share of Changchun high-new total profits has risen to more than 70%.
first half of 2020, Changchun High-rise in the beginning of the pediatric clinic limited, the business net profit is still up 80%, which shows the importance of growth hormone cash flow.
,100 yuan, or 5.10 percent, with a 1.17 percent change rate.
information, Murray Medical was founded in 1991 and its main products cover three major areas: life information and support, in-body diagnostics, and medical imaging.
company has more than 30 countries with overseas subsidiaries, products and solutions are exported to more than 190 countries and regions around the world.
from overseas revenue situation, the company's overseas revenue in the first half of the year reached 5,013 million yuan, an increase of 46.82 percent, accounting for 47.45 percent of total revenue, the international market significantly accelerated.
Industry generally believes that, with China's efforts to strengthen the replacement of health system construction, hospital reform and expansion of health systems and medical equipment imports, as well as the release of related beneficial industrial policies, Meirui Medical as a leader in the medical device industry will benefit in the long term.
at the same time, Murray's cost-effective product advantages in overseas markets will be further reflected, or usher in better opportunities.
new closing price of 306.50 yuan, up 3.46 percent, the change rate of 16.01 percent.
is committed to the development, production and sale of innovative vaccine companies.
march 2019, Consino Bio landed on the Hong Kong Stock Exchange and its share price has skyrocketed since 2020.
, the company's share price was only HK$59.85 per share on January 2, 2020, according to The Wind.
on May 21st, the share price was as high as HK$285.8 per share, with an amplitude of 38.94 per cent on the day.
highs in early 2000, Consino rose as much as 377.5 per cent.
on August 13th, Concino officially landed on the board, and the share price closed at HK$198.8 per share, reaching a high of HK$477 per share, but the share price began to fall half a month later.
industry analysts believe that the recent pharmaceutical industry and vaccine stocks are facing a relatively large adjustment, so in addition to raising the valuation after the run, the sector valuation adjustment may also be one of the reasons for the accelerated decline of stocks such as Consino.